

STUDY HIGHLIGHTS

JULY 29, 2011

COST EFFECTIVENESS RESEARCH AND PILOTS—INTERVIEW WITH DR. DECHAIRO



Bryan Dechairo, Ph.D.

Sr. Director, Head of Extramural Research and Development, MedcoResearch Institute

MRC: What area of the Research Institute do you work in?

B. Dechairo: I lead the Extramural Research and Development arm of the Medco Research Institute. We focus on partnering with external companies to evaluate the cost effectiveness of implementing innovative pilot programs.

MRC: Can you tell us about some of your active projects?

B. Dechairo: We have two actively enrolling pilots—one in Rheumatoid Arthritis and the other in Inflammatory Bowel Disease. Each focus on therapeutic monitoring to optimize currently administrated immunosuppressant therapy in patients in order to improve outcomes and delay progression to more aggressive biologic therapies. Additionally, we have a research study that

focuses on members with Schizophrenia or Bipolar Disorder. The study attempts to validate the clinical utility of a genetic test for improving accuracy of antipsychotic prescribing.

MRC: How do you select which projects to do?

B. Dechairo: We actively look for healthcare innovations across all disease indications that may benefit Medco clients and members. Once an area is identified we prioritize projects based on current client drug spend and trends focusing first on the opportunities within the areas of highest client drug spend.

MRC: How will your projects benefit members and clients?

B. Dechairo: Members benefit by having earlier access to cutting edge healthcare advances which may improve their response to therapies leading to improved outcomes and quality of life. For clients, our efforts may provide an earlier insight into the cost effectiveness of novel healthcare interventions while not incurring additional cost during the project.

DID YOU KNOW...

Medco clients help drive research studies and projects conducted by the Medco Research Institute. Results that may potentially affect your member population as well as drug spend are known after studies and pilot programs fully enroll members. Member enrollment is dependent on client approval. Because of this, please consider granting your approval for the Medco Research Institute to contact your members who might be eligible for a study or pilot program. For more information, please contact your account team or Research Institute, Client Relations at 301-771-2629 or mrc@medco.com.

Upcoming Medco Research Consortium Events:

August, 2011

Distribution of the Research Consortium Newsletter—inaugural issue to focus on Diabetes.

...

August 23 MRC Webinar:

Diabetes and Research
(Invitations forthcoming)

...

Medco Research Institute is nominating patients 100 years of age and older who may be interested in participating in an initiative that includes whole genome sequencing. If you would like to learn more, please contact the Client Relations team at mrc@medco.com.

Are you interested in hearing how research conducted at Medco might affect your member population? If yes—please contact your account team or Medco Research Institute Client Relations at 301-771-2629 or mrc@medco.com.